CD44 Antikörper
Kurzübersicht für CD44 Antikörper (ABIN3025613)
Target
Alle CD44 Antikörper anzeigenReaktivität
Wirt
Klonalität
Konjugat
Applikation
Klon
-
-
Aufreinigung
- Protein G affinity chromatography
-
Immunogen
- Purified CD44 antigen (PGp-1) from lymphocyte membrane was used as the immunogen for the CD44 antibody.
-
Isotyp
- IgG1 kappa
-
-
-
-
Applikationshinweise
-
Optimal dilution of the CD44 antibody should be determined by the researcher.
1. Staining of formalin/paraffin tissues requires boiling tissue sections in 10 mM Citrate buffer, pH 6.0, for 10-20 min followed by cooling at RT for 20 min.
2. The prediluted format is supplied in a dropper bottle and is optimized for use in IHC. After epitope retrieval step (if required), drip mAb solution onto the tissue section and incubate at RT for 30 min.\. Western blot: 1-2 μg/mL, Flow Cytometry: 0.5-1 μg/million cells in 0.1ml,Immunofluorescence: 0.5-1 μg/mL,Immunohistochemistry (FFPE): 0.5-1 μg/mL for 30 min at RT (1),Prediluted format: incubate for 30 min at RT (2) -
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Konzentration
- 1 mg/mL
-
Buffer
- 1 mg/mL in 1X PBS, BSA free, sodium azide free
-
Konservierungsmittel
- Azide free
-
Lagerung
- 4 °C,-20 °C
-
Informationen zur Lagerung
- Store the CD44 antibody at 2-8°C (with azide) or aliquot and store at -20°C or colder (without azide).
-
-
- CD44
-
Andere Bezeichnung
- CD44
-
Hintergrund
- Recognizes a cell surface glycoprotein of 80-95 kDa (CD44/HCAM) on lymphocytes, monocytes, and granulocytes (Leucocyte Typing Workshop V). Its epitope is resistant to digestion by trypsin and chymotrypsin. The CD44 family of glycoproteins exists in a number of variant isoforms, the most common being the standard 85-95 kDa or hematopoietic variant (CD44s). Higher molecular weight isoforms are described in epithelial cells (CD44v), which are believed to function in intercellular adhesion and stromal binding. CD44 immunostaining is commonly used for the discrimination of urothelial transitional cell carcinoma in-situ from non-neoplastic changes in the urothelium.
-
Pathways
- Glycosaminoglycan Metabolic Process, Autophagie, Negative Regulation of intrinsic apoptotic Signaling
Target
-